AMA's Recent Approval Marks a Milestone for Innoblative's SIRA Device in Breast Cancer Treatment

Significant Steps Forward in Breast Cancer Treatment

The American Medical Association (AMA) has recently approved a Category III Current Procedural Terminology (CPT) code for Innoblative Designs, Inc.'s innovative SIRA® RFA Electrosurgical Device. This approval, announced on March 3, 2026, represents a significant milestone for the company in addressing urgent clinical needs for breast cancer patients. The SIRA device is designed to assist in intraoperative radiofrequency ablation during breast conservation surgery, and its CPT code designation will come into effect in 2027. This development provides a formal avenue for tracking real-world data concerning its use, outcomes, and financial implications in healthcare settings.

Richard Stark, the CEO of Innoblative, expressed the company’s enthusiasm regarding the AMA's decision, stating, "This strong signal of SIRA's clinical credibility and market readiness is monumental for future integration into practice." The approval sets up a necessary foundation for broader clinical use, creates a standardized framework for efficacy data collection, and positions the SIRA device for future reimbursement and commercial success.

Understanding the SIRA Technology

The SIRA device stands out as a first-of-its-kind technology aimed at enhancing the safety and effectiveness of breast conservation surgery (BCS). Its unique spherical design enables circumferential delivery of radiofrequency (RF) energy, facilitating consistent depth of ablation throughout the surgical cavity. By ensuring well-defined ablation margins, clinicians can better address concerns about leftover cancerous tissue that could require further surgical procedures, thereby aiming to lower the rates of both positive margins and subsequent reoperations.

Breast cancer remains a pressing global health issue, with many patients facing difficult choices in their treatment journey following a diagnosis. BCS, while recommended in many cases, often comes with a rather high reoperation rate – estimated at approximately 20%. For patients undergoing this surgery, the risk of requiring follow-up procedures to eliminate residual cancer can be daunting.

Furthermore, treatment often advances to requiring radiation therapy, which entails multiple sessions over weeks and brings with it a variety of side effects that can severely affect a patient's quality of life. Innoblative focuses on providing a viable alternative that reduces these burdens and enhances patient care.

The Future of SIRA: Goals and Expectations

The SIRA device, currently investigational in the United States, aspires to offer a one-time, non-ionizing therapeutic alternative to traditional radiation therapies. Through further clinical validation, the goal remains to reduce overall healthcare costs while improving patient outcomes in breast cancer treatment. The introduction of the CPT code is expected to elevate its profile within the medical community, facilitating broader adoption and potentially leading to better treatment protocols.

In conclusion, with the AMA's recent approval, Innoblative's SIRA device is well-positioned to make a meaningful difference in the future of breast cancer care, providing an innovative approach that aims to improve surgical outcomes and ultimately, the lives of those affected by this disease. For more detailed information on this device and Innoblative's comprehensive mission, visit Innoblative.com.